Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to investigate the effect of IN-A001 50mg on the pharmacokinetics of Tacrolimus 5mg in healthy volunteers
This is a open-label, 1-sequence, 2-period, multiple oral dose, phase 1 study. Healthy subjects will be assigned to a group and sequentially administerd Tacrolimus and IN-A001.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Period 1: A; Period 2: B and C | Experimental | A: Oral Administration of Tacrolimus 5mg once / B: Oral Administration of IN-A001(Tegoprazan) 50mg QD for 7 days / C: Oral Administration of IN-A001(Tegoprazan) 50mg + Tacrolimus 5mg once |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tacrolimus | Drug | Tacrolimus 5mg (1 mg * 5 capsules) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmax of Tacrolimus | Maximum Plasma Concentration at Steady State of Tacrolimus | up to 72 hours(period 1), up to 240 hours(period 2) |
| Tmax of Tacrolimus | Time to Cmax at steady state | up to 72 hours(period 1), up to 240 hours(period 2) |
| AUClast of Tacrolimus | Area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration | up to 72 hours(period 1), up to 240 hours(period 2) |
| AUCinf of Tacrolimus | Area under the curve from time 0 extrapolated to infinite time | up to 72 hours(period 1), up to 240 hours(period 2) |
| T1/2β of Tacrolimus | Half-life of the drug during elimination phase | up to 72 hours(period 1), up to 240 hours(period 2) |
| Measure | Description | Time Frame |
|---|---|---|
| Point estimates and 90% CI for log (GMR of Period 2 Cmax, AUClast, AUCinf) / log (GMR of Period 1 Cmax, AUClast, AUCinf) of Tacrolimus | log(GMR of Period 2 Cmax, AUClast, AUCinf) / log (GMR of Period 1 Cmax, AUClast, AUCinf) | up to 72 hours(period 1), up to 240 hours(period 2) |
| Cmax of Tegoprazan |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Has clinically significant infections
Has a history of malignancy
Has a history of gastrointestinal disease that may affect the absorption of investigational product.
Has genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose absorption disorder etc.
History of hypersensitivity and severe allergic reaction to any of the components of IP.
Has participated in any other clinical study, etc. and received IPs within 180 days prior to the screening visit.
Excessive smoking (> 10 cigarettes/day) within 14 days prior to the screening visit.
Excessive drinking ((> 21 units/week) within 14 days prior to the screening visit.
Has shown the following results from the laboratory test during the screening period.
Has shown the following results during the 12-lead electrocardiogram during the screening period.
Determined ineligible for study participation by the investigator for other reasons.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sohyun Kim | Contact | 82-2-6477-0225 | sohyun.kim21@inno-n.com | |
| Nagyung Kim | Contact | 82-2-6477-0195 | nagyung.kim@inno-n.com |
| Name | Affiliation | Role |
|---|---|---|
| Kyun-Seop Bae, MD, PhD | Asan Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asan Medical Center | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| D016559 | Tacrolimus |
| ID | Term |
|---|---|
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| IN-A001(Tegoprazan) | Drug | IN-A001 50mg(Tegoprazan 50mg* 1 tablet) |
|
|
| IN-A001(Tegoprazan) + Tacrolimus | Drug | IN-A001 50mg(Tegoprazan 50mg*1 tablet) and Tacrolimus 5mg(1mg * 5capsules) |
|
|
Maximum Plasma Concentration at Steady State of Tegoprazan |
| up to 240 hours(period 2) |
| Tmax of Tegoprazan | Time to Cmax at steady state | up to 240 hours(period 2) |
| AUClast of Tegoprazan | Area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration | up to 240 hours(period 2) |
| AUCinf of Tegoprazan | Area under the curve from time 0 extrapolated to infinite time | up to 240 hours(period 2) |
| T1/2β of Tegoprazan | Half-life of the drug during elimination phase | up to 240 hours(period 2) |